Roche to pay more than US$1b for majority stake in tumour-testing company
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
THE Swiss pharmaceutical giant Roche said on Monday that it would acquire a majority of the tumour-testing company Foundation Medicine for more than US$1 billion, in a deal aimed at improving both cancer treatment and drug development.
Foundation is the leader in the growing area of sequencing the genes of tumour samples, looking for mutations that can help predict which drug will be most effective for a particular patient.
Share with us your feedback on BT's products and services
TRENDING NOW
Autobahn Rent A Car directors declared bankrupt over S$50 million each owed to DBS
Amazon’s MGM Studios gains creative control over ‘James Bond’ franchise
UOB’s Wee Ee Cheong says S$4.9 billion Citi deal ‘paying off’ as Asean push accelerates
In taxing wealth, how far can Singapore push property owners?
